Try our beta test site
315 studies found for:    "Mesothelioma"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Tomotherapy Treatment for Mesothelioma
Condition: Mesothelioma
Intervention: Procedure: Tomotherapy
2 Unknown 
Has Results
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Oxaliplatin/Gemcitabine
3 Not yet recruiting A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Tremelimumab;   Drug: Durvalumab
4 Unknown  Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Velcade (bortezomib) plus Eloxatin (oxaliplatin)
5 Completed
Has Results
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Condition: Mesothelioma
Interventions: Drug: pemetrexed disodium;   Drug: gemcitabine hydrochloride;   Drug: carboplatin
6 Unknown  Vinorelbine in Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Vinorelbine;   Other: Active Symptom Control
7 Completed
Has Results
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Condition: Mesothelioma
Interventions: Drug: bevacizumab;   Drug: cisplatin;   Drug: pemetrexed
8 Unknown  Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
Condition: Mesothelioma
Intervention:
9 Terminated
Has Results
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Vinorelbine;   Drug: Vandetanib
10 Recruiting Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Condition: Mesothelioma
Intervention:
11 Recruiting A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Condition: Pleural Mesothelioma
Interventions: Drug: Pembrolizumab;   Drug: Cisplatin and Pemetrexed
12 Completed Dendritic Cell-based Immunotherapy in Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Biological: tumor lysate-loaded autologous dendritic cells
13 Unknown  Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery
Condition: Malignant Mesothelioma
Interventions: Drug: chemotherapy;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
14 Active, not recruiting Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Condition: Mesothelioma
Interventions: Drug: Nivolumab;   Drug: Nivolumab + Ipilimumab
15 Recruiting PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma
Condition: Mesothelioma
Intervention: Radiation: Prophylactic Irradiation of Tracts (PIT)
16 Completed Serum Biomarkers in Diagnosis of Mesothelioma
Condition: Mesothelioma
Intervention: Biological: Mesothelin, hyaluronan, osteopontin, syndecan-1
17 Completed Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Cisplatin;   Drug: Imatinib Mesylate;   Drug: Pemetrexed;   Drug: Dexamethasone
18 Completed Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Erlotinib;   Drug: Bevacizumab
19 Completed Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays
Condition: Peritoneal Mesothelioma
Intervention: Genetic: comparative genomic analysis
20 Withdrawn A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Vorinostat;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.